ストックスクリーナーアプリを入手
12.24
7.50%
-1.16
前日終値:
$13.40
開ける：
$14
24時間の取引高:
186.93K
Relative Volume:
0.59
時価総額：
$410.79M
収益：
-
当期純損益:
$-47.20M
株価収益率:
-7.8196
EPS:
-1.5653
ネットキャッシュフロー:
$-43.65M
1週間 パフォーマンス:
-6.66%
1か月 パフォーマンス:
+18.05%
6か月 パフォーマンス:
+17.60%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$11.80
$14.24
1週間の範囲:
$11.80
$14.74
52週間の値動き範囲:
$4.8069
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
MBX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
12.29 | 436.86M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.11 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.87 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.15 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.00 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
278.14 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | JP Morgan | Overweight |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Stifel | Buy |
Mbx Biosciences Inc (MBX) 最新ニュース
Oppenheimer initiates MBX Biosciences stock with Outperform rating By Investing.com - Investing.com India
Oppenheimer initiates coverage on MBX Biosciences with 'outperform' - TradingView
MBX Biosciences stock maintains Market Outperform rating at JMP - Investing.com
Why MBX Biosciences Inc. stock attracts strong analyst attentionFree Discussion Group - Newser
How MBX Biosciences Inc. stock performs during market volatilityFree Stock Market Knowledge Sharing - Newser
What makes MBX Biosciences Inc. stock price move sharplyFree Investment Community - Newser
MBX Biosciences stock maintains Market Outperform rating at JMP on strong Yorvipath launch - Investing.com
Insiders Rewarded With US$78k Addition To Investment As MBX Biosciences Stock Hits US$359m - 富途牛牛
MBX Biosciences, Inc.(NasdaqGS: MBX) dropped from Russell 2000 Growth Index - MarketScreener
MBX Biosciences, Inc. (NYSE:MBX) Given Average Rating of “Buy” by Analysts - Defense World
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development - GlobeNewswire
Strategic Growth and Clinical Advancements Propel MBX Biosciences to a Buy Rating - TipRanks
MBX Biosciences files IND application for MBX-4291 for obesity - BioWorld MedTech
MBX Biosciences announces IND application to FDA for MBX 4291 - TipRanks
MBX Biosciences Submits IND for Obesity Treatment - TipRanks
MBX Biosciences submits IND for once-monthly obesity treatment - Investing.com
MBX Biosciences Announces IND Submission Of MBX 4291, Its Long-Acting GLP1/GIP Receptor Co-Agonist Prodrug For The Treatment Of Obesity - MarketScreener
MBX Biosciences Announces IND Submission of MBX 4291, its - GlobeNewswire
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor ... - Eagle-Tribune
Bank of America Corp DE Makes New Investment in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Stifel reiterates buy rating on MBX Biosciences stock ahead of trial data - Investing.com Nigeria
Stifel reiterates buy rating on MBX Biosciences stock ahead of trial data By Investing.com - Investing.com South Africa
MBX Biosciences Announces Presentations on MBX 1416 at American Diabetes Association’s 85th Scientific Sessions - Nasdaq
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions - GlobeNewswire
MBX Biosciences Phase 1 Success: Revolutionary Weekly Treatment for Post-Bariatric Hypoglycemia Heads to Phase 2 - Stock Titan
MBX Biosciences Updates Corporate Presentation June 2025 - TipRanks
Nuveen Asset Management LLC Purchases Shares of 14,471 MBX Biosciences, Inc. (NYSE:MBX) - Defense World
BNP Paribas Financial Markets Makes New Investment in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
mbx biosciences announces board changes and director elections - Investing.com Australia
mbx biosciences announces board changes and director elections By Investing.com - Investing.com South Africa
MBX Biosciences, Inc. Announces Departure of Carl L. Gordon from the Company's Board of Directors, Effective June 5, 2025 - marketscreener.com
MBX Biosciences Elects Directors at Annual Meeting - TipRanks
Deutsche Bank AG Buys New Position in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases Shares of 6,335 MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy - Seeking Alpha
MBX Biosciences, Inc. (NYSE:MBX) Given Consensus Rating of “Buy” by Brokerages - Defense World
MBX Biosciences, Inc. (NYSE:MBX) Shares Sold by Millennium Management LLC - Defense World
Northern Trust Corp Invests $1.67 Million in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences to Participate in June Investor Conferences - GlobeNewswire
MBX Biosciences Showcases Precision Peptide Pipeline at Two Major Healthcare Conferences This June - Stock Titan
Citadel Advisors LLC Grows Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences, Inc. (NYSE:MBX) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
MBX Biosciences Reports Q1 2025 Financial Progress - TipRanks
MBX Biosciences, Inc.: Strong Buy Rating Amid Promising Phase II Data and Robust Financial Position - TipRanks
Stifel maintains MBX Biosciences stock Buy rating, $40 target By Investing.com - Investing.com Nigeria
Stifel maintains MBX Biosciences stock Buy rating, $40 target - Investing.com
MBX Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Mbx Biosciences Inc (MBX) 財務データ
収益
当期純利益
現金流量
EPS
Mbx Biosciences Inc (MBX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Feb 18 '25 |
Buy |
10.84 |
143,170 |
1,551,963 |
3,255,000 |
| GORDON CARL L | Director |
Feb 14 '25 |
Buy |
9.87 |
47,502 |
468,793 |
3,205,930 |
| ORBIMED ADVISORS LLC | Director |
Feb 18 '25 |
Buy |
10.84 |
143,170 |
1,551,963 |
3,255,000 |
| ORBIMED ADVISORS LLC | Director |
Feb 14 '25 |
Buy |
9.87 |
47,502 |
468,793 |
3,205,930 |
| Hawryluk P. Kent | President & CEO |
Feb 04 '25 |
Buy |
10.69 |
50,000 |
534,500 |
448,277 |
| Mathers Edward T | Director |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| BASKETT FOREST | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Behbahani Ali | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Chang Carmen | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Florence Anthony A. Jr. | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
3.43%
1.52%
大文字化:
|
ボリューム (24 時間):